Director/PDMR Shareholding

Summary by AI BETAClose X

BioPharma Credit PLC announced that Sapna Shah, a Director, purchased 42,500 ordinary shares at $0.94 per share on March 25, 2026, for a total transaction value of $39,950.00, equivalent to £29,902.27. This transaction occurred on the London Stock Exchange.

Disclaimer*

BioPharma Credit PLC
25 March 2026
 

BIOPHARMA CREDIT PLC

 

Notification of Transactions by

Persons Discharging Managerial Responsibilities and

Persons Closely Associated with them

 

1.

Details of person discharging managerial responsibilities/person closely associated with them

a)

Name

Sapna Shah

2.

Reason for the notification

a)

Position / status

Director of BioPharma Credit PLC

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

BioPharma Credit PLC

b)

LEI

213800AV55PYXAS7SY24

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares of $0.01 each

 

 

GB00BDGKMY29

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.94

42,500

d)

Aggregated information

- Aggregated volume

 

- Price

 

 

42,500

 

$39, 950.00 (Converted to GBP @ 1.336019 = £29,902.27)

e)

Date of the transaction

25.03.2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings